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Abstract Hypertension in obese children may require a
different diagnostic and treatment approach from that for
children with secondary hypertension, yet there is neither
consensus nor a clear guideline. The aim of this study was
to assess how obese children with hypertension are cur-
rently diagnosed and treated by paediatric nephrologists,
what obstacles exist and what can be improved. In the
period May–November 2014, an online questionnaire was
sent to all members of the European Society for Paediatric
Nephrology (n = 2148). Questions focused on current
practices and obstacles regarding screening, diagnosis and
treatment of hypertension in obese children. A total of 214
paediatric nephrologists responded. Although nearly 100 %
agreed that screening of obese children for hypertension is
indicated, it was current practice in only 56 % of partici-
pating countries; 88 % of respondents diagnosed hyper-
tension with 24-h ambulatory blood pressure measurement.
Diagnostics used to rule out causes or consequences of
hypertension varied among the respondents; they included,
in particular, the use of serum renin/aldosterone, urine
sodium/potassium, and dimercaptosuccinic acid scan.
Concerning treatment, 45 % of respondents preferred to
start treatment with a lifestyle program, 2 % with antihy-
pertensive medication, and 40 % with both. For 73 % of
respondents, angiotensin-converting enzyme-inhibitors or
angiotensin receptor blockers were the drugs of first choice.
The findings of this study emphasize the urgent need for an
international guideline for screening, diagnosis and treat-
ment of hypertension in obese children.
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Introduction
Overweight and obesity in children continues to be an
increasing public health problem. As overweight and
obesity are important risk factors for elevated blood pres-
sure, hypertension is increasingly diagnosed in children as
well. The prevalence of hypertension in (non-selected)
schoolchildren aged 3–18 years of normal weight is
3–5 %, with overweight 4–14 %, and in obese children
11–33 % [1–6]. If not identified and treated early, hyper-
tension can lead to atherosclerosis, cardiovascular disease
and renal failure, and impose an important burden of dis-
ease [7].
The (US) National High Blood Pressure Education
Program (NHBPEP) Working group on High Blood Pres-
sure in Children and Adolescents (Fourth Report) as well
as the European Society of Hypertension have provided
guidelines for the diagnosis and treatment of hypertension
[8, 9]. However, hypertension in obese children may need a
different diagnostic and treatment approach from that for
children with secondary hypertension. Obesity-related
hypertension, often referred to as primary hypertension, is
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often less severe and less symptomatic in comparison to
secondary hypertension [10]; thus, for example, a consul-
tation with an ophthalmologist to check for hypertensive
retinopathy might not be necessary. In addition, a lifestyle
intervention might suffice as treatment for hypertension in
obesity, whereas secondary hypertension most likely
requires pharmacological treatment [11]. However, there is
neither consensus nor a clear guideline regarding the
screening, diagnosis and treatment of obese children with
hypertension.
The aim of this study was to assess how obese children
with hypertension are currently diagnosed and treated by
paediatric nephrologists, and to explore possible obstacles
to their management and what should be improved.
Methods
Current practice of screening, diagnosis and treatment of
hypertension in obese children was investigated through an
online questionnaire (SurveyMonkey, Palo Alto, CA,
USA). The questionnaire (including up to two reminders)
was sent to all members of the European Society for Pae-
diatric Nephrology (n = 2148) in the period May–
November 2014. The questionnaire consisted of 18 ques-
tions: 16 closed- and two open-ended questions (see Sup-
plementary information 1). The questions focused on
current practices and obstacles regarding screening, diag-
nosis and treatment of hypertension in obese children and
suggestions to improve these aspects. The closed-ended
questions were analysed with Microsoft Excel 2010. Data
are expressed as percentages of respondents. The statistical
analyses were performed with SPSS software version 20.0
(SPSS Inc., Chicago, IL, USA). Differences in diagnostics
and treatment of hypertension between Europe and Asia
were tested with X2 tests. For the analysis of the open-
ended questions, the answers were first coded according to
an open-coded technique, because of the explorative nature
of the open questions. The codes were then categorized
into themes, which resulted in a list of topics representing
the most frequent answers. By combining the codes under
overarching categories, a clear outline of the relevant
information was provided.
Results
A total of 214 paediatric nephrologists filled out the
questionnaire. Of the respondents, 65 % worked in Europe,
25 % in Asia, 4 % in South America, 3 % in Oceania and
2 % in North America. For the number of respondents per
country, see Supplementary information 2. Concerning
their employment, 70 % (n = 164) worked at a university
hospital, 18 % (n = 43) in a general hospital, 9 %
(n = 21) in a private clinic, and 2 % (n = 5) in a paedi-
atric hospital.
According to 97 % (203/209) of the respondents, all
obese children should be screened for hypertension; the
remaining 3 % (6/209) felt this should be done only in
specific situations, e.g. when there is need to see a doctor,
or if risk factors such as a positive family history for
hypertension or metabolic syndrome are present. In 56 %
(30/54) of the participating countries, obese children were
currently screened for hypertension; in 20 % (11/54) of the
countries contradictory answers within the country were
given regarding whether or not obese children were
screened for hypertension. According to 86 % (131/152) of
the respondents who indicated that children are screened
for hypertension in their country, screening was done by a
paediatrician, in 32 % (49/152) by a general practitioner,
and in 32 % (49/152) by preventive child health care
(school nurse or physician) (multiple answers possible).
Table 1 shows who performs the screening per continent.
According to 88 % (174/197) of paediatric nephrolo-
gists, diagnosis of hypertension in obese children is per-
formed by means of 24-h ambulatory blood pressure
measurement (ABPM). There was no significant difference
in use of ABPM to diagnose hypertension between
respondents in Europe and Asia. If hypertension is diag-
nosed in obese children, several tests can be done to rule
out other (secondary) causes of hypertension. Figure 1a–c
display which tests were performed by the respondents. In
Asia, significantly more paediatric nephrologist (92 %)
refer obese children with hypertension to an ophthalmol-
ogist to check for hypertensive retinopathy in comparison
to paediatric nephrologists in Europe (63 %) (p = 0.003).
In Europe, tests for both plasma renin/aldosterone
(p = 0.003) and urinary sodium/potassium (p = 0.02) are
more frequently performed (respectively 64 and 66 %)
than in Asia (respectively 43 and 42 %).
When hypertension is diagnosed in obese children, 45 %
(88/195) of the respondents preferred to start treatment
with a lifestyle program, 2 % (4/195) started with antihy-
pertensive medication, and 40 % (78/195) with both. In
addition, several paediatric nephrologists mentioned that
the treatment of choice depends on the stage and severity of
the hypertension and the presence of target organ damage.
If a lifestyle program is preferred but hypertension per-
sisted, 9 % (10/113) would start antihypertensive treatment
after 12 months, 60 % (68/113) after 6 months, 13 % (15/
113) after 3 months, 3 % (3/113) after 1 month, and 12 %
(14/113) answered that it depends on the severity of the
hypertension, and the presence of symptoms and target
organ damage. There was no significant difference between
Europe and Asia. Significantly more paediatric nephrolo-
gists in Europe (78 %) preferred angiotensin-converting
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enzyme (ACE)-inhibitors or angiotensin receptor blockers
as the drug of first choice in comparison to paediatric
nephrologists in Asia (58 %) (p = 0.01). 42 % of paedi-
atric nephrologists in Asia preferred calcium antagonist as
opposed to 22 % of European paediatric nephrologists. The
use of beta-blockers and diuretics among the respondents
was negligible. Table 1 shows the preferred options for
treatment of hypertension in obese children per continent.
The respondents experienced several obstacles regard-
ing screening, diagnosis and treatment of hypertension in
obese children. A frequently mentioned bottleneck was the
non-compliance of parents and children to treatment.
Respondents stated that parents and children often have a
lack of knowledge concerning obesity and hypertension,
and a reluctant attitude towards its treatment and care.
Another frequently mentioned bottleneck was the lack of
necessary equipment, e.g. an ABPM, lack of appropriate
blood pressure reference tables, and of appropriate size
cuffs for primary screening by health care professionals. In
addition, poor screening structures were reported as an
obstacle: lack of infrastructure for the screening for
hypertension in referrals and a lack of personnel. In addi-
tion, scarce and low-quality treatment programmes for
obesity in children were mentioned. The frequency of the
mentioned obstacles per continent is shown in Table 2.
The respondents provided several suggestions for
improving the screening, diagnosis and treatment of
hypertension in obese children: (1) to establish an adequate
system for screening for hypertension in all obese children,
e.g. at school; (2) to raise national awareness of obesity and
hypertension as a serious public health problem; (3) to
establish educational programs for physicians, especially
family doctors, on the principles of hypertension in obese
children; (4) to create international guidelines on the
screening, diagnosis and treatment of hypertension specific
for obese children, including international reference values
for blood pressure; (5) to make available equipment, such
as an ABPM and several cuff sizes for primary care, and
finances necessary for the implementation of screening; (6)
that the treatment and counselling of obese children (with
hypertension) be carried out by a multidisciplinary team
including nutritionists, psychologists, physical education
teachers, and specialized nurses; (7) that supervision of the
treatment of obese hypertensive children should, however,
be done by paediatricians or paediatric nephrologists and
not by general practitioners.
Discussion
Nearly all paediatric nephrologists were convinced that
obese children should be screened for hypertension and
nearly all regarded ABPM as the preferential diagnostic
tool for confirming the diagnosis of hypertension. The
respondents generally agreed on the need to perform a
series of diagnostic tests to rule out secondary causes of
Table 1 Screening for
hypertension and preferred
options for treatment of
hypertension in obese children,
per continent
Total Europe Asia N. America S. America Oceania
Screening done by
Paediatrician 133 (57) 97 (55) 23 (70) 4 (40) 6 (75) 3 (50)
General practitioner 49 (21) 36 (21) 5 (15) 3 (30) 2 (25) 3 (50)
Preventive healthcare 50 (22) 42 (24) 5 (15) 3 (30) – –
Preferred treatment
Lifestyle program 112 (57) 78 (58) 22 (55) 2 (40) 5 (63) 2 (40)
Medication 4 (2) 3 (2) 1 (3) – – –
Both 79 (41) 54 (40) 17 (43) 3 (60) 3 (38) 3 (60)
Start medication
After 12 months 10 (9) 10 (13) – – – –
After 6 months 69 (63) 48 (63) 14 (64) 1 (50) 3 (60) 3 (60)
After 3 months 13 (12) 8 (11) 3 (14) 1 (50) – 1 (20)
After 1 months 3 (3) – 2 (9) 1 (20) –
Depends on patient 13 (12) 10 (13) 3 (14) 1 (20) 1 (20)
Preferred medication
Diuretics 2 (1) 2 (20 – – – –
Beta-blocker 5 (3) 4 (3) 1 (3) – – –
Calcium antagonist 45 (23) 27 (21) 16 (40) – – 3 (43)
ACE-I/ARB 138 (73) 98 (74) 22 (55) 5 (100) 7 (100) 4 (57)
ACE-I angiotensin-converting enzyme (ACE)-inhibitors, ARB angiotensin receptor blockers
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Fig. 1 Use of diagnostic tests
by paediatric nephrologists
(n = 241) in obese children
with hypertension to rule out
other (secondary) causes of
hypertension. a Diagnostic
blood tests. b Diagnostic urine
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hypertension and to look for consequences of hypertension
(e.g. renal function, urine microalbumin, and ultrasound of
heart and kidneys). However, plasma renin/aldosterone and
a dimercaptosuccinic acid (DMSA) renal scan were
regarded as unnecessary in obese children by half of the
paediatric nephrologists. The majority of respondents
(60 %) said they would aim to start antihypertensive
medication within 6 months if lifestyle intervention was
unsuccessful in reducing the blood pressure.
In a survey conducted among paediatric nephrologists in
North America in 2005, ABPM was used by 63 % of
respondents to diagnose or monitor primary hypertension
in children [12]. In our study, ABPM was used by 88 % of
the respondents; hence, in the last decade the use of ABPM
seems to have increased. However, according to the
European Society of Hypertension and the Fourth Report,
ABPM should be used in selected cases and not as the
golden standard for diagnosing hypertension in children [8,
9]. Existing normative values are based on relatively small
groups of children, and there is need for expansion of
reference values for paediatric ABPM. Although ABPM
could certainly provide important information, interpreta-
tion of ABPM readings should be handled cautiously [8, 9,
13].
A possible consequence of hypertension in children is
left ventricular hypertrophy. Almost 90 % of paediatric
nephrologists in our sample perform an ultrasound of the
heart to identify left ventricular hypertrophy in hyperten-
sive obese children, as recommended by the European
Society of Hypertension and the Fourth Report for all
children with hypertension, not specifically for obese
children with hypertension [8, 9]. A less common conse-
quence of childhood hypertension is hypertensive
retinopathy. In Asia, obese children with hypertension are
significantly more often referred to an ophthalmologist to
check for hypertensive retinopathy than in Europe. Studies
on the effect of elevated blood pressure on retinal
vasculature in children are limited and results are contra-
dictory [14, 15]. To the best of our knowledge, there are no
studies on the presence of retinal vascular abnormalities
specifically in obese hypertensive children.
The most frequent causes of secondary hypertension in
children are of renal origin [9, 16]. Almost all paediatric
nephrologists in our study determine plasma creatinine and
perform an ultrasound of the kidneys. This is in accordance
with the recommendations of the European Society of
Hypertension and the Fourth Report for all children with
hypertension, not specifically for obese children with
hypertension [8, 9]. Another point to highlight is that only
60 % of paediatric nephrologists in Europe and 40 % of
paediatric nephrologists in Asia measure the plasma con-
centration of electrolytes in order to detect secondary forms
of hypertension (e.g. hyperaldosteronism, although rare in
children), even though this is recommended by the guide-
lines [8, 9].
Of the respondents, 42 % indicated that treatment
should start with antihypertensive medication, and the
majority of these stated it should be alongside a lifestyle
programme. However, the European Society of Hyperten-
sion and the Fourth Report recommend that pharmaco-
logical treatment should be used in selected cases and only
if a lifestyle programme has not accomplished enough
change in blood pressure [9]. There was a significant dif-
ference in drug of first choice between Europe and Asia: in
Europe ACE-inhibitors or angiotensin receptor blockers
were significantly more often indicated as the drug of first
choice than in Asia. ACE-inhibitors are recommended as
the drug of first choice in obese hypertensive adults [17],
and in children with primary hypertension [12]. Limited
data are available on pharmacological treatment of hyper-
tension specific for obese children.
Paediatric nephrologists perceived as an important
obstacle the lack of consensus and guidelines for the
diagnosis and treatment of hypertension specific for obese
Table 2 Most important obstacles experienced by paediatric nephrologists regarding screening, diagnosis and treatment of hypertension in
obese children, per continent
Total Europe Asia N. America S. America Oceania
Non-compliance 78 (35) 41 (28) 27 (55) 4 (50) 5 (50) 1 (14)
Poor BP screening structures 36 (16) 21 (14) 9 (18) 3 (38) 1 (10) 2 (29)
Inadequate obesity treatment programmes 23 (10) 20 (14) 1 (2) – – 2 (29)
Lack of clear reference values and cuff sizes 18 (8) 12 (8) 5 (10) – 1 (10) –
Lack of ABPM 12 (5) 9 (6) 3 (6) – – –
Lack of awareness of the problem as a healthcare issue 12 (5) 10 (7) 1 (2) – – 1 (14)
Poor diagnosis and treatment structures for hypertension 41 (19) 33 (23) 3 (6) 1 (13) 3 (30) 1 (14)
Total 220 (100) 146 (100) 49 (100) 8 (100) 10 (100) 7 (100)
BP blood pressure, ABPM ambulatory blood pressure monitoring
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children. A lack of consensus regarding evaluation and
management of hypertensive children has previously been
recognized [12]. Uniformity in diagnosis and treatment of
hypertension is of great importance in order to reliably
determine the presence of comorbidity of obesity, and to be
able to examine the effectiveness of treatment programs.
The most frequently mentioned suggestion for
improvement of the current situation was to establish an
adequate protocol for screening for hypertension in all
obese children, e.g. at school. Yet, if a system of screening
for hypertension is established there should also be
opportunities for the diagnosis and treatment of obese
children with hypertension.
A topic debated in the recent literature [1, 18–20] concerns
the issue whether or not there should be separate reference
values for overweight and obese children versus normal
weight children. The reference values provided by the Fourth
Report are based on both non-overweight and overweight or
obese children [21]. Schwandt et al. argue that since over-
weight and obese children have substantially higher blood
pressure values, separate blood pressure percentiles should be
used for them. This would allow overweight and obese chil-
dren to have a higher normal blood pressure than non-over-
weight children [1]. However, as Urbina and Falkner argue, an
increased blood pressure in children imposes an increased risk
for target organ damage and cardiovascular events [18]. Since
the same is true for overweight and obese children, they should
not intentionally be exposed to higher risks for adverse out-
comes of elevated blood pressure. It could be argued that
reference values should be based on normal weight children
alone. Using reference values based on both normal weight
and overweight/obese children combined leads to the risk that
normal weight children with an elevated blood pressure may
not be identified, since overweight and obese children raise the
cut-off values [19].
A limitation of this study is the low response rate (10 %).
The 214 respondents who completed questionnaires pro-
vided interesting information about current practice and
expressed the need for improvements. However, these
results may not be generalizable. Unfortunately, we do not
have information about the non-respondents. It would have
been interesting to compare characteristics of respondents
versus non-respondents, such as type of practice (academic
vs. private), region (country, and small town vs. large city).
It is possible, therefore, that a selection bias has occurred.
Another limitation is the small number of respondents per
continent. Comparative analyses between the continents
could not be performed due to the small numbers within the
groups. Therefore, only Europe and Asia were compared.
However, it is not a surprise that most continents were not
well represented since the questionnaire was sent to mem-
bers of the European Society for Paediatric Nephrology, and
only European respondents were expected.
A limitation of the questionnaire is that it did not
address what criteria are used by the respondents to diag-
nose hypertension (e.g. the definitions provided by the
Fourth Report or local national blood pressure percentiles)
or what criteria are used to diagnose obesity in children
(e.g. body mass index percentiles provided by the US
Center for Disease Control and Prevention, or the World
Health Organisation, or local national body mass index
percentiles, or the classification of the International Obesity
Task Force).
A strength of the study is the broad variety of countries
that participated, 54 countries in total, which provided a
clear view of the current practice in different countries and
cultures and what clinical care gaps are experienced.
Although respondents from all countries indicated the need
for an international guideline, it is questionable if having
worldwide consensus on screening, diagnosis and treat-
ment of hypertension in obese children, and thereby cre-
ating one universal guideline, is possible. Because of major
differences between different parts of the world in terms of
socioeconomics, genetics, etc., one international guideline
might not be useful, and it would probably be preferable to
create a basic model for a guideline and then adapt it for
different parts of the world.
Conclusion
The findings of this study emphasize the urgent importance of
having clear recommendations and an international guideline
for the screening, diagnosis and treatment of hypertension in
obese children, since hypertension in obese children may need
a different diagnostic and treatment approach from that suit-
able for children with secondary hypertension.
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